SCHEMBL6338190

SCHEMBL6338190

COC(=O)c1ccccc1NC(=O)c1ccc(Oc2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.66
HPGD P15428 4/20 0.66
ALDH1A1 P00352 3/20 0.66
MAPT P10636 1/20 0.66
SMN1; SMN2 Q16637 6/20 0.65
NPC1 O15118 5/20 0.65
RAB9A P51151 5/20 0.65
SENP7 Q9BQF6 2/20 0.65
CASP3 P42574 1/20 0.65
TAAR1 Q96RJ0 1/20 0.65
TSHR P16473 4/20 0.60
HSD17B10 Q99714 4/20 0.60
LMNA P02545 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C19 P33261 1/20 0.60
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
ELANE P08246 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291513 0.96 KDM4E (0.69) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL6336997 0.92 MAPT (0.66) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL6349053 0.88 KDM4E (0.56) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL2290505 0.87 KDM4E (0.67) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL2294814 0.86 SENP7 (0.74) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL2291128 0.86 KDM4E (0.66) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL2290164 0.85 SMN1; SMN2 (0.76) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6349025 0.85 ELANE (0.70) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL6349020 0.85 ALDH1A1 (0.60) KDM4EHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL2277733 0.84 KDM4E (0.64) KDM4EHPGDALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 KDM4E 875/4885HPGD 1438/4885ALDH1A1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.